LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

Search

Simulations Plus Inc

Open

SectorHealthcare

17.04 -1.79

Overview

Share price change

24h

Current

Min

16.91

Max

17.43

Key metrics

By Trading Economics

Income

-70M

-67M

Sales

-2.1M

20M

P/E

Sector Avg

48.528

105.69

Dividend yield

0.48

Profit margin

-330.585

Employees

243

EBITDA

327K

5.3M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-7.67% downside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.48%

2.37%

Next Earnings

1 gru 2025

Market Stats

By TradingEconomics

Market Cap

-5.6M

346M

Previous open

18.83

Previous close

17.04

News Sentiment

By Acuity

50%

50%

182 / 374 Ranking in Healthcare

Simulations Plus Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 lis 2025, 21:55 UTC

Earnings

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12 lis 2025, 21:34 UTC

Earnings

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12 lis 2025, 23:44 UTC

Market Talk

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12 lis 2025, 23:38 UTC

Market Talk

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12 lis 2025, 23:13 UTC

Earnings

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12 lis 2025, 23:13 UTC

Earnings

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12 lis 2025, 23:13 UTC

Earnings

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12 lis 2025, 23:13 UTC

Earnings

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12 lis 2025, 22:30 UTC

Market Talk
Earnings

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12 lis 2025, 22:18 UTC

Earnings

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12 lis 2025, 22:12 UTC

Market Talk

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12 lis 2025, 22:05 UTC

Earnings

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12 lis 2025, 22:04 UTC

Earnings

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12 lis 2025, 22:04 UTC

Earnings

Pan American Silver 3Q Adj EPS 48c >PAAS

12 lis 2025, 22:04 UTC

Earnings

Pan American Silver 3Q Rev $884.4M >PAAS

12 lis 2025, 22:04 UTC

Earnings

Pan American Silver 3Q EPS 45c >PAAS

12 lis 2025, 22:03 UTC

Earnings

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12 lis 2025, 22:02 UTC

Earnings

Manulife Financial 3Q Net C$1.8B >MFC

12 lis 2025, 22:02 UTC

Earnings

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12 lis 2025, 22:02 UTC

Earnings

Manulife Financial 3Q EPS C$1.02 >MFC

12 lis 2025, 21:53 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12 lis 2025, 21:53 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12 lis 2025, 21:53 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12 lis 2025, 21:53 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12 lis 2025, 21:52 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12 lis 2025, 21:51 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12 lis 2025, 21:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

12 lis 2025, 21:49 UTC

Earnings

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12 lis 2025, 21:48 UTC

Earnings

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12 lis 2025, 21:40 UTC

Earnings

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Peer Comparison

Price change

Simulations Plus Inc Forecast

Price Target

By TipRanks

-7.67% downside

12 Months Forecast

Average 16 USD  -7.67%

High 16 USD

Low 16 USD

Based on 4 Wall Street analysts offering 12 month price targets forSimulations Plus Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Sentiment

By Acuity

182 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat